1[1]Schauer U, Echhart A, Muller R, et al. Enhanced leukotriene C4production by peripheral eosinophilic granulocytes from children with asthma[J]. Int Arch Allergy Appl Immunol. 1989, 90:201-206.
2[2]Azevodo I, de Blic J, Scheinmann P, et al. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants[J ].Modulation by dexamethasone. Am J Respir Crit Care Med. 1995,152:1208-1214.
3[3]VolovitzB, FudenH, Ogra PL. Release of leukotriene C4 in respiratory tract during acute viral infection[J ]. J Pediatr. 1988, 112:218-222.
4[4]Adelroth E, Morris MM, Hargreave FE, etal. airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients withasthmaand normal controls[J]. N Engl J Med. 1986,315:480-484.
5[5]Bisgaard H, Lerche A, Kristensen JK. Leukotriene-and histamine induced increases in vascular permability and interstial trannsport in the skin. J invest Permatol. 1985,84:427-429.
6[6]Bisgaard H, Olsson P, BendeM. Effect of leukotriene D4 on asal mucosal blood flow, nasal airway resistance and nasal secretion in humans[J]. Clin Allergy. 1986,16:289-297.
7[7]Bisgaard H, Pederson M. SRS-A leukotrienes decrease the activity of human respiratory cilia[J]. Clin Allergy. 1987,17:95-103.
8[8]Zileuton for asthma. MedLett. 1997;39:18.
9[9]AdkinsJC, Brogden RN. Zafrilukast. Areviewof its pharmacology and therapeutic patential in the management of asthma[J ]. Drugs.1998, 55:121-144.
10[10]SpectorSL, Smith LJ, GlassM. Effects of weeks oftherapywith oral doses of ICI, 219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma,ACCOLATE Asthma Trialist Group[J]. AmJ Respir Crit Care Med. 1994,204;150:618-623.
同被引文献6
1Parks DP, Ahrens RC, Humphries T, et al. Chronic cough in child-hood: appronch todiagnosis and treatment [J]. J Pediatr,1989, 115: 856.
2Pizzichinic EJA, left TF, Reiss L, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized controlied trial [J]. Eur Respir J, 1999, 12: 1184-1190.
